EyeControl
Description
The EyeControl device is the first communication device that enables locked-in individuals to communicate using only eye movements, without the need for a screen. With this simple to use and wearable device, patients can communicate 24/7 with their loved ones and caregivers.
Our initial launch is currently taking place in the UK where we have connected with Augmentative and Alternative Communication hubs around England that will assist in assessing each patient and implementing our device for appropriate individuals. Additionally, we have established relationships with NGOs globally. In fact, one of our co-founders, Shay Rishoni, was an ALS patient himself, as well as the President of ALS NGO Prize4Life until his passing in May 2018. Shay committed the company to donate 10% of all future revenue to the NGO for the support of ALS patients, as well as the research into the debilitating disease.
Our competitive pricing means that the EyeControl device will be available and accessible to people from most socio-economic backgrounds. We are working with the Israeli and UK governments to subsidize the device.
Our company is built on a strong foundation of individuals with a personal connection and to Motor Neuron Diseases. Eleven years ago I lost my beloved grandmother to ALS, Itai Kornberg, our CTO, lost a close friend from a debilitating neurological disease and Shay Rishoni, our third co-founder, was an ALS patient himself until his passing in May this year. These experiences serve as the driving force behind our dedication to the project.<br />
Based in Tel Aviv, we have a growing research and development team under the leadership of Itai Kornberg, and a business-marketing team under the leadership of Or Retzkin. Since the company’s establishment at the beginning of 2016, the company has grown to include 10 employees from various backgrounds around the country who work together in our Tel Aviv offices.
SDGS & Targets
Goal 3
Ensure healthy lives and promote well-being for all at all ages
3.1
3.1.1
Maternal mortality ratio
3.1.2
Proportion of births attended by skilled health personnel
3.2
3.2.1
Under-five mortality rate
3.2.2
Neonatal mortality rate
3.3
By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases
3.3.1
Number of new HIV infections per 1,000 uninfected population, by sex, age and key populations
3.3.2
Tuberculosis incidence per 100,000 population
3.3.3
Malaria incidence per 1,000 population
3.3.4
Hepatitis B incidence per 100,000 population
3.3.5
Number of people requiring interventions against neglected tropical diseases
3.4
3.4.1
Mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease
3.4.2
Suicide mortality rate
3.5
Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol
3.5.1
Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders
3.5.2
Alcohol per capita consumption (aged 15 years and older) within a calendar year in litres of pure alcohol
3.6
3.6.1
Death rate due to road traffic injuries
3.7
By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes
3.7.1
Proportion of women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods
3.7.2
Adolescent birth rate (aged 10-14 years; aged 15-19 years) per 1,000 women in that age group
3.8
Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all
3.8.1
Coverage of essential health services
3.8.2
Proportion of population with large household expenditures on health as a share of total household expenditure or income
3.9
3.9.1
Mortality rate attributed to household and ambient air pollution
3.9.2
Mortality rate attributed to unsafe water, unsafe sanitation and lack of hygiene (exposure to unsafe Water, Sanitation and Hygiene for All (WASH) services)
3.9.3
Mortality rate attributed to unintentional poisoning
3.a
3.a.1
Age-standardized prevalence of current tobacco use among persons aged 15 years and older
3.b
Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all
3.b.1
Proportion of the target population covered by all vaccines included in their national programme
3.b.2
3.b.3
Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis
3.c
3.c.1
Health worker density and distribution
3.d
Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks
3.d.1
International Health Regulations (IHR) capacity and health emergency preparedness
3.d.2
Percentage of bloodstream infections due to selected antimicrobial-resistant organisms
SDG 14 targets covered
Deliverables & Timeline
Resources mobilized
Partnership Progress
Feedback
Share
Timeline
Entity
SDGs
Geographical coverage
More information
Countries
Contact Information
Or Retzkin, Co-Founder, CEO